Ocuphire Pharma Investor Updates slide image

Ocuphire Pharma Investor Updates

P 30 Potential 'Best in Class' Presbyopia Drop Competitive Approaches Limited by Safety/Tolerability, Durability, and Poor Distance Night Vision Nyxol + LDP Presbyopia Treatment is Differentiated: ✓ Statistically significant efficacy data ✓ Favorable safety profile ✓ Comfort and tolerability ✓ Fast onset ✓ Long duration ✓ Maintain good distance visual acuity (night/day) ✓ Novel tunable pupil modulation Ocuphire PHARMA
View entire presentation